The company

Business model

Avergen Pharmaceutical GmbH (APG) creates long-term value through internal and collaborative innovative drug discovery programs based on novel drug targets. APG is dedicated on its core competences in neurodegenerative diseases indications. APG is focused on drug development until phase II clinical studies. The location of the company in Munich enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

Company registration

Handelsregister beim Amtsgericht München, Nr. HRB 217756

Vertreten wird die Avergen Pharmaceuticals GmbH durch seinen Geschäftsführer: Dr. med. Marius Yildiz

Umsatzsteueridentifikationsnummer: DE300119217

Zuständige Aufsichtsbehörde: Regierung von Oberbayern

Adresse: Am Klopferspitz 19, 82152 Martinsried, Germany